Reversal of submaxillary salivary alterations in cystic fibrosis by guanethidine.
D000681:Amylases / Q000032:analysis; D001949:Bretylium Compounds / Q000494:pharmacology; D002118:Calcium / Q000032:analysis; D003550:Cystic Fibrosis / Q000503:physiopathology*; D006145:Guanethidine / Q000494:pharmacology*; D006801:Humans; D009438:Neuraminic Acids / Q000032:analysis; D009573:Nitrites / Q000494:pharmacology; D009584:Nitrogen / Q000032:analysis; D010646:Phentolamine / Q000494:pharmacology; D011188:Potassium / Q000032:analysis; D012110:Reserpine / Q000494:pharmacology; D012463:Saliva / Q000032:analysis*; D012964:Sodium / Q000032:analysis; D013363:Submandibular Gland / Q000187:drug effects*; D014439:Tyramine / Q000494:pharmacology
D001949:Bretylium Compounds; D009438:Neuraminic Acids; D009573:Nitrites; D012110:Reserpine; D012964:Sodium; D000681:Amylases; D009584:Nitrogen; D011188:Potassium; D002118:Calcium; D014439:Tyramine; D010646:Phentolamine; D006145:Guanethidine